E-resources
Peer reviewed
-
Zhang, Zhanzhan; Yue, Yu‐Xin; Xu, Lina; Wang, Ying; Geng, Wen‐Chao; Li, Juan‐Juan; Kong, Xiang‐lei; Zhao, Xinzhi; Zheng, Yadan; Zhao, Yu; Shi, Linqi; Guo, Dong‐Sheng; Liu, Yang
Advanced materials (Weinheim), 03/2021, Volume: 33, Issue: 12Journal Article
Combination chemotherapy refers to the use of multiple drugs to treat cancer. In this therapy, the optimal ratio of the drugs is essential to achieve drug synergism and the desired therapeutic effects. However, most delivery strategies are unable to precisely control the ratio of the drugs during the drug loading and delivery processes, resulting in inefficient synergy and unpredictable efficacy. Herein, a macrocyclic‐amphiphile‐based self‐assembled nanoparticle (MASN) that achieves precise loading and ratiometric delivery of therapeutic combinations is presented. By integrating multiple macrocyclic cavities within a single nanoparticle, the MASN can load multiple drug molecules via the host–guest interaction, and the ratio of the drugs loaded can be predicted with their initial concentrations and characteristic binding affinity. Moreover, MASNs are readily degraded under a hypoxic microenvironment, allowing spontaneous release of the drugs upon reaching tumor tissues. With precise drug loading and controlled release mechanisms, MASNs achieve ratiometric delivery of multiple commercial drugs to tumors, thereby achieving optimal anti‐tumor effects. Since the optimal drug ratio of a therapeutic combination can be quickly determined in vitro, MASNs can translate this optimal ratio to the therapeutic benefits in vivo, providing a potential platform for the rapid development of effective combination cancer therapies involving multiple drugs. A macrocyclic‐amphiphile‐based self‐assembled nanoparticle (MASN) with the capability of precise loading and ratiometric delivery of different drugs is developed for effective combination chemotherapy. The MASN can quickly convert the optimal drug ratio of a therapeutic combination identified in vitro into therapeutic benefits in vivo, providing a potential platform for the rapid development of effective combinations of cancer therapies.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.